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Muscular dystrophies are genetically diverse but share common phenotypic features of muscle weakness, degeneration, and
progressive decline in muscle function. Previous work has focused on understanding how disruptions in the dystrophin-
glycoprotein complex result in muscular dystrophy, supporting a hypothesis that the muscle sarcolemma is fragile and susceptible
to contraction-induced injury in multiple forms of dystrophy. Although benign in healthy muscle, contractions in dystrophic
muscle may contribute to a higher degree of muscle damage which eventually overwhelms muscle regeneration capacity. While
increased susceptibility of muscle to mechanical injury is thought to be an important contributor to disease pathology, it is
becoming clear that not all DGC-associated diseases share this supposed hallmark feature. This paper outlines experimental
support for a function of the DGC in preventing muscle damage and examines the evidence that supports novel functions for
this complex in muscle that when impaired, may contribute to the pathogenesis of muscular dystrophy.
1.Introduction
Skeletal muscle is a dynamic tissue that routinely under-
goes a signiﬁcant degree of mechanical strain and cellular
deformation with each contraction. In order to preserve
normal skeletal muscle function throughout the lifetime of
an individual, this complex tissue must be able to routinely
undergo cell shortening and generate forces required for
movement while at the same time limiting mechanical
cellular injury and adapting to changing workloads. In
muscular dystrophy, an imbalance between muscle damage
or degeneration and muscle repair through stem-cell medi-
ated regeneration is thought to contribute to the disease
pathology and consequently results in a progressive decline
in muscle function [1]. Mutations in a number of distinct
genes can cause muscular dystrophy with varying degrees of
severity, but precisely how each can negatively aﬀect normal
muscle function is unclear [2]. A signiﬁcant number of
muscular dystrophies result from mutations that aﬀect the
normal assembly of the dystrophin-glycoprotein complex at
the sarcolemma in muscle. A longstanding hypothesis to
explain the high degree of muscle damage and degeneration
observed in dystrophic muscle is that mutations aﬀect the
function of critical structural proteins in muscle and in
some way compromises the mechanical stability of the
muscle ﬁber and/or its sarcolemma. This exacerbates the
damage that occurs during normal muscle contractions and
initiates a lethal cascade of events that can cause death
of the myoﬁber [3–5]. In support of this, early studies
demonstrated an increase in the number of necrotic ﬁbers in
musclesfrommusculardystrophypatientsthatlikelyresulted
from irreparable membrane damage as a consequence of
normal muscle activity [6]. However, rather than dystrophic
muscle suﬀering from an increased susceptibility to external
damage, alternative hypotheses exist that could account for
increased cell death. For example, that causative mutations
may aﬀect either the resting homeostasis of muscle cells or
alter the ability of the muscle to adapt and repair following
a normal “dose” of muscle injury. Although the importance
of the dystrophin-glycoprotein complex in maintaining
sarcolemma integrity is well supported, alternative functions2 Journal of Biomedicine and Biotechnology
for this complex have been proposed through the years and
are now gaining signiﬁcant experimental support [7, 8].
2. The Dystrophin-Glycoprotein Complex
The dystrophin-glycoprotein complex (DGC) is composed
of several transmembrane and peripheral components and
is highly expressed in the sarcolemma of skeletal muscle
[9–11]. Mutations in genes that encode DGC components
lead to the loss of either expression and/or function of the
DGC in muscle. Dystroglycan is a protein central to this
complex that spans the sarcolemma and binds to ligands
in the surrounding basal lamina through α-dystroglycan
and to dystrophin inside the cell through β-dystroglycan
[12]. Dystrophin in turn binds to the submembrane actin
andintermediateﬁlamentcytoskeletonwithinﬁbers,thereby
completing a link between the cytoskeleton and the extra-
cellular matrix [13, 14]. Costameres are concentrations of
extracellular matrix receptor complexes that reside at the
membrane in register with the Z-lines of sarcomeres within
muscle ﬁbers. The location of the DGC at costameres and
the identiﬁcation of its function as a link between the matrix
and the cytoskeleton has led to the hypothesis that the DGC
might be critical in mechanically stabilizing muscle or the
sarcolemma during muscle contraction [12, 15].
In addition to dystroglycan and dystrophin, the core
of this complex in skeletal muscle is also formed by four
sarcoglycans (α, β, γ,a n dδ) and sarcospan, which are
thought to contribute to stabilization of the complex within
thesarcolemma.Mutationsineitherdystrophin orthesarco-
glycansareassociatedwithreducedexpressionorincomplete
formationoftheDGC[16–18]andarehypothesizedtoresult
inmusculardystrophythroughacommonmechanismwhich
includes a reduction in dystroglycan function. Therefore,
reduction in the connections between the cytoskeleton
and the extracellular matrix appears critical to muscular
dystrophies associated with the DGC.
In addition to primary mutations in DGC components,
several causative mutations have also been identiﬁed in
a group of glycosyltransferases, which have been shown
to function in a common pathway to glycosylate α-
dystroglycan. This O-linked glycosylation of α-dystroglycan
is essential for enabling α-dystroglycan to function as an
extracellular matrix receptor [19]. In these glycosylation-
deﬁcient muscular dystrophies, dystroglycan and the DGC
are expressed and intact at the sarcolemma, but the loss of
the ability of dystroglycan to bind laminin is suﬃcient to
cause muscular dystrophy [20, 21]. These ﬁndings highlight
speciﬁcally the interaction of the DGC with extracellular
matrix as a critical function of the DGC in preventing
muscular dystrophy.
In the dystroglycan glycosylation-deﬁcient mice
(LARGEmyd) electron microscopic analysis showed that
the interaction of dystroglycan with laminin in the
extracellular matrix appeared to tightly anchor the basal
lamina to the sarcolemma [21]. This tight and regular
interaction of dystroglycan with the basal lamina is proposed
to protect the sarcolemma from expansion of small ruptures
during mechanical activity. Mutations in dystroglycan
itself appear to be quite rare in humans, perhaps related
to an essential role of dystroglycan in early development
[22]. Only recently has a mutation in the dystroglycan
gene been identiﬁed in muscular dystrophy patients and
like previous glycosyltransferase mutations, the mutation
appears to impair dystroglycan glycosylation and causes loss
of function without impacting dystroglycan expression [23].
The heterotrimeric protein laminin-211 is a major
component of the basal lamina surrounding adult muscle
ﬁbers that is bound by glycosylated α-dystroglycan (α-DG).
Mutations in the LAMA2 gene result in loss of laminin
α2 expression and the most common form of congenital
muscular dystrophy [24–26]. The identiﬁcation of laminin
α2 mutations only further reinforces the notion that any
disruption of the connection between the muscle ﬁber
cytoskeleton to the extracellular matrix through the DGC,
whether it be reduced expression of the DGC, reduced ability
of dystroglycan to interact with laminin, or loss of laminin
itself from the basal lamina, is suﬃcient to cause muscular
dystrophy.
Despite the ﬁrst genetic identiﬁcation of dystrophin as
a causal gene in Duchenne muscular dystrophy more than
t w od e c a d e sa g o[ 27] and the identiﬁcation of the DGC in
years following [16], whether the DGC contributes purely a
mechanical role in stabilizing the sarcolemmaduring normal
contractions or imparts other signiﬁcant functions in muscle
stillremainsanareaofactiveinvestigation.Theidentiﬁcation
of additional components of the DGC, such as sarcospan,
dystrobrevins, and syntrophins, that do not appear to have a
directoressentialroleinthemechanicalfunctionoftheDGC
but instead appear to be docking sites for other intracellular
signaling proteins [28], has fueled considerable interest in
what other intracellular pathways may be aﬀected in DGC-
associated muscular dystrophies.
3. The DGC,Sarcolemma Integrity,
andContraction-Induced MuscleInjury
Even normal skeletal muscle is susceptible to mechanical
damage, particularly during lengthening contractions, and
immediate defects at the level of the sarcolemma [29], the
t-tubules [30], or the contractile machinery [31]c o n t r i b u t e
to a transient decrease in the isometric force. Following
repetitive lengthening contractions, there can also be con-
siderable, prolonged injury and muscle dysfunction that
results from muscle degeneration, swelling, and inﬁltration
ofinﬂammatorycells[32].Inmostcases,muscledysfunction
caused by prolonged injury can be fully repaired over time
by active muscle ﬁber regeneration from resident stem
cells, known as satellite cells. This suggests that occasional
sarcolemmal injuries, muscle damage, and their repair might
beacriticalcomponentofthehomeostasisofnormalmuscle.
Many of the early experiments that sought to identify
the mechanism by which mutations aﬀecting the DGC cause
musculardystrophyhaveutilizedthemdxmousemodel[33].
These mice harbor a null mutation in the dystrophin gene
and although they do exhibit the clinical features observed
in human patients, the severity is milder [34]. A role forJournal of Biomedicine and Biotechnology 3
the function of dystrophin in maintaining the integrity of
the sarcolemma during muscle contraction was supported
by studies showing that mdx muscle was highly susceptible
to lengthening contraction-induced injury performed in
vitro, as compared to healthy control muscle. Muscle from
mdx animals demonstrated an increased tendency to take
up Procion orange dye from the bathing medium, which
suggested an increase in sarcolemma permeability following
contraction [4, 35]. When injected into mdx animals, the
membrane-impermeant Evans blue dye was also selectively
taken up by muscle ﬁbers that appeared necrotic and were
hypercontracted, which suggested that increased membrane
permeability eventually resulted in cell death [36]. This
further supported the hypothesis that muscle contractions
produce membrane tears, which lead to an increase in
permeability of the sarcolemma to calcium and small
molecules and results in a greater degree of cell death in
dystrophicmuscle.Musclefrommdxmicealsodemonstrated
a measurable deﬁcit in force generation following an in
vivo lengthening contraction protocol [37, 38]. These data
support a function for dystrophin and the dystrophin-
glycoprotein complex, at least partially, in protecting the
sarcolemma during muscle contraction and suggest that, in
its absence,the sarcolemmais more susceptible todamage by
contractile forces, resulting in increased permeability of ions
and small molecules, and eventual cell necrosis and muscle
degeneration.
Further support for a critical role of membrane integrity
in muscular dystrophies was gained from a diﬀerent class
of muscular dystrophies associated with mutations in the
dysferlin gene. Mutations in dysferlin are associated with
Miyoshi myopathy and limb girdle muscular dystrophy 2B
in humans [39, 40]. Dysferlin is not associated with the
DGC but appears to have homology to the vesicle protein,
synaptotagmin, and therefore has been predicted to be
important for mediating vesicle-mediated membrane repair.
While the complete functions of dysferlin are still under
investigation, dysferlin has been shown to be required for
rapid resealing of the sarcolemma in a calcium-dependent
manner following focal membrane damage [41]. Although
muscle from dysferlin-null animals is not particularly sus-
ceptible to contraction-induced damage any more so than
healthy muscle [42], a recent study demonstrated that
recovery of muscle following damage required an immediate
and transient membrane resealing event and that dysferlin-
deﬁcient muscle consequently took longer to recover [42,
43]. The identiﬁcation of dysferlin as a potential mediator
of membrane repair in muscle underlies the importance
of sarcolemmal integrity and its maintenance by repair
pathways as important mechanisms in which defects may
result in muscle degeneration.
4.Does Contraction-InducedInjuryPlay
aCausalRoleinDGC-AssociatedMuscular
DegenerationandDystrophy?
While the generally accepted dogma is that mutations
aﬀecting the DGC render muscle more susceptible to
contraction-induced damage during mechanical stress [44],
recent evidence from our laboratory suggests that not
all muscles of dystrophic animals are equally aﬀected.
We reported that, in the LARGEmyd animal model of
glycosyltransferase-deﬁcient muscular dystrophy, typical
fast-twitchmusclessuchastheEDLwereweakerthancontrol
WT EDL muscles. Additionally, LARGEmyd EDL muscles
demonstrated the increased susceptibility to contraction-
induced injury typical of EDL muscles of mdx mice, as
indicated by a dramatic loss of force following lengthening
contraction that was signiﬁcantly greater than controls [45].
However, a remarkably diﬀerent phenotype was measured
in soleus muscles, which are composed of mixtures of fast
and slow ﬁbers [45]. Although the contraction protocol
resulted in a 26% force deﬁcit in WT soleus muscle, there
was no greater increase in force deﬁcit observed in the
soleus of LARGEmyd mice. Force deﬁcits measured in WT
soleus muscle were also higher than those measured in EDL
muscle after two lengthening contractions, which suggested
that the observed defect was not due to inherent diﬀerences
in susceptibility to injury between the two muscle groups,
nor to diﬀerences in dystroglycan glycosylation or laminin
binding activity. However, the soleus of LARGEmyd animals
was still weaker than WT muscle and dystrophic, as evi-
denced by an increase in degenerating ﬁbers, accumulation
ofinﬂammatorycells,andthepresenceofcentrallynucleated
ﬁbers. An explanation that accounts for the dystrophic
features and ﬁber degeneration in the soleus muscle in
the absence of any detectable increased susceptibility to
contraction-induced injury has not been addressed.
A similar lack of increased susceptibility of muscle to
contraction-induced muscle damage was previously demon-
strated in the soleus of mdx mice, and the authors speculated
that dystrophin was not essential for maintaining structural
stability in the soleus muscle [37]. Utrophin, a homologue
of dystrophin, has been shown to be upregulated in the
absence of dystrophin [46] and is also more highly expressed
in slow-twitch ﬁbers [47] which may therefore confer a
degree of stability in the soleus muscle of mdx mice that
might explain this lack of susceptibility to contraction-
induced injury. However, upregulation of utrophin can-
not explain the results in LARGEmyd mice because, other
than the loss of dystroglycan glycosylation, the DGC is
assembled normally in LARGEmyd muscle [20, 21]. We
found that another important laminin receptor in muscle,
α7β1 integrin, is expressed at much higher levels in the
sarcolemma of soleus muscle as compared to other fast
muscles [45]. Several reports have demonstrated that when
the DGC is impaired, α7o rβ1 integrin is upregulated,
which suggests that the two receptors may have at least
some overlapping functions in muscle [48]. Susceptibility to
contraction-induced injury was directly compared between
α7 integrin-null and LARGEmyd mice using EDL muscle and
only LARGEmyd muscle was shown to be more susceptible
to injury [21]. This might suggest that interactions with
lamininanddystroglycanaremoreimportantformechanical
stability than are the interactions between α7β1 integrin
and laminin. However, α7β1 integrin expression in fast
muscle is very low, and the comparison was only shown4 Journal of Biomedicine and Biotechnology
in fast-twitch muscle, and not in the soleus muscle, which
remains to be studied. Transgenic overexpression of α7
integrin in dystrophin/utrophin double knockout mice can
signiﬁcantly improve muscle disease [49], but whether this
beneﬁcial eﬀect is due to prevention of mechanical damage
or eﬀects on cell signaling has not been fully addressed.
The potential role of integrins and the DGC in laminin-
dependentsignalinginmuscleisdiscussedingreaterdetailin
Section 6.
Muscle physiological studies have also been performed
in an animal model of congenital muscular dystrophy, the
dy/dy mouse, that harbors a null mutation in the LAMA2
gene [24]. In contrast to the results demonstrated in mdx
mice, laminin-deﬁcient muscle does not exhibit a defect in
sarcolemmal stability [50]. Both the EDL and soleus muscles
were isolated from laminin-deﬁcient mice and subjected
to a moderate lengthening contraction protocol in vitro
and neither demonstrated an increased susceptibility to
injury over that observed in control muscle. As a means
to amplify potentially subtle defects in these mice, the
anesthetic halothane was used to increase ﬂuidity of the
lipid bilayer. Although this did cause an increase in force
deﬁcit following a lengthening contraction protocol, this
deﬁcit was still not any greater in laminin-deﬁcient muscle
[50]. Because contraction protocols can vary, sarcolemmal
permeability was directly compared between three diﬀer-
ent mouse models of DGC-related muscular dystrophy,
mdx [33] and two deﬁcient in laminin, dy/dy [24]a n d
dy2j/dy2j [25]. Animals were injected intravenously with
Evans blue dye and muscles were analyzed several hours
after injection. Muscles from mdx demonstrated an increase
in dye uptake while dye uptake in laminin-deﬁcient muscle
was not diﬀerent than control animals [51]. Additionally,
positively stained ﬁbers in mdx m i c eo f t e na p p e a r e di n
groups of neighboring ﬁbers, in contrast to the few indi-
vidual ﬁbers stained in laminin-deﬁcient muscle, which
appeared necrotic. However, laminin-deﬁcient muscle still
had dystrophic pathological features, which further supports
the notion that, although disruption of the sarcolemma may
contribute to the pathology of muscle disease, it is not
essential.
Together, these studies demonstrate that membrane
damage is not required for muscle degeneration and mus-
cular dystrophy. Although mutations that compromise DGC
function can leave muscle vulnerable to membrane damage,
this is not true for all muscle groups, since the soleus
muscle, despite demonstrating a susceptibility to injury
in healthy muscle, does not show increased susceptibility
in the absence of a functional DGC. Additionally, the
number of ﬁbers that may be damaged, as evidenced by
d y eu p t a k ei nmdx fast muscles, is not suﬃcient to explain
the dramatic loss in force generation following injury [37].
Therefore, the DGC likely possesses other cellular functions
in skeletal muscle that, when impaired, contribute to muscle
degeneration and the dystrophic pathology. Potential alter-
native pathways and their experimental support are reviewed
below.
5. Role of the DGC in
AlteredCalciumHomeostasis
Intracellular calcium is a critical mediator of several
regulatory processes in skeletal muscle [52]. In dystrophic
muscle,theconcentrationofintracellularcalciumiselevated,
and several potential sources for calcium entry have now
been identiﬁed (Figure 1). Early studies of mdx muscle
demonstrated that individual ﬁbers that showed an elevation
in intracellular calcium were also necrotic, which suggested
that calcium entered through membrane tears as a direct
result of dystrophin loss [53, 54]. Increased intracellular
calcium in mdx muscle was later explained by an increase
in sarcolemmal permeability attributed to calcium leak
and stretched-activated channels [55, 56]. Stretch-activated
channels can be blocked in mdx mice via oral delivery
of streptomycin and results in a reduction in intracellular
calcium and an improvement in force production [57]. In
the same study, a decrease in intracellular calcium was not
observed in streptomycin-treated control animals, which
suggested that the activity of these channels was somehow
enhanced in the absence of dystrophin.
The transient receptor potential (TRP) channels are a
diverse family of ion channels composed of multiple sub-
units, that have also been identiﬁed as potential mediators
of altered calcium homeostasis in dystrophic muscle [58].
Several TRP channels in the canonical subfamily (TRPC) are
expressed in mouse skeletal muscle and TRPC1, TRPC4, and
TRPC6 were initially identiﬁed as being potentially impaired
in mdx muscle [59]. In a later study, expression of TRPC1
was shown to be increased in mdx muscle and the authors
speculatedthatitsactivitymaybeincreasedduetoadditional
upregulation of caveolin-3 and src, which contribute to
the translocation of this channel to the sarcolemma [60].
Similarly, a stretch-activated TRP channel in the vanilloid
receptor subfamily, TRPV2, has also been shown to be
more highly expressed at the sarcolemma in mdx muscle.
Inhibition of TRPV2 using a dominant negative genetic
approach resulted in a restoration of normal intracellular
calcium levels and an amelioration of dystrophic pathology
in mdx mice [61].
Although the increased resting calcium concentration
observed in the cytoplasm of dystrophic muscle may be
the result of increased expression or activity of calcium
channels atthesarcolemma,a recentstudy hasdemonstrated
that an additional source of calcium entry may be due
to defects at the level of the sarcoplasmic reticulum [62].
RyR1 channels isolated from mdx muscle were shown to
be hypernitrosylated as a potential consequence of altered
nitric oxide signaling downstream of dystrophin loss. This
resulted in an increased leak of calcium ions from the
sarcoplasmic reticulum, and pharmacological inhibition of
RyR1 was shown to reduce muscle damage in mdx muscle.
While several of these studies noted an improvement
in muscle health following inhibition of calcium entry in
animal models of muscular dystrophy, an important study
recently demonstrated that elevated calcium was suﬃcient
to cause muscle damage in the absence of a genetic basis
for muscular dystrophy [63]. The overexpression of TRPC3Journal of Biomedicine and Biotechnology 5
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Figure 1: Sources of calcium entry in dystrophic muscle. (1) Disruptions to the DGC can result in instability of the sarcolemma that permits
calcium entry through membrane tears when the sarcolemma is stretched during lengthening muscle contractions. (2) Activity of calcium
leak, stretch-activated, and various TRP channels has been shown to be increased in dystrophin-deﬁcient muscle and their inhibition in vivo
can improve dystrophic pathology. (3) The ryanodine receptor has recently been shown to be hypernitrosylated in mdx muscle which may
result in an increased leak of calcium from the sarcoplasmic reticulum.
in skeletal muscle resulted in a muscle wasting phenotype
with defects similar to those observed in laminin-deﬁcient
muscle. Using gene expression proﬁling, this phenotype
was also shown to be associated with altered expression
of many genes, in a pattern that was strikingly similar to
gene expression changes in δ-sarcoglycan deﬁcient muscle.
However, the muscle did not demonstrate any changes in
expression of the DGC at the sarcolemma, which suggests
that much of the muscle damage observed in DGC-related
muscular dystrophies may be attributed to downstream
defects in calcium homeostasis.
Elevated intracellular calcium can result in cellular
damage in a number of ways that may underlie many of
the defects observed in dystrophic muscle. When sustained,
abnormal elevations in intracellular calcium can cause mito-
chondriatoundergopermeabilitytransitionwhichcaneven-
tually lead to mitochondrially mediated apoptosis, involving
swelling of the mitochondria, release of cytochrome c,
and the activation of caspases [64]. Cyclophilin D is a
mitochondrial enzyme that is important for regulating the
mitochondrial permeability transition and genetic strategies
have demonstrated that its absence renders mitochondria
insensitive to calcium-induced cell death [65, 66]. Both δ-
sarcoglycan-null and laminin-null mice have abnormally
swollen mitochondria and the muscular dystrophy seen in
both models can be partially alleviated by altering the pores
mediating the mitochondrial permeability transition [67].
Another important downstream consequence of mito-
chondrial dysfunction is an increased production of reactive
oxygen species (ROS), which can further exacerbate cellular
damage [68]. Several studies have identiﬁed ROS as a
potential mediator of muscle damage in the muscular
dystrophies [69–71]. Antioxidant treatment of mdx mice has
demonstrated mixed results but in some cases has lessened
the symptoms of muscular dystrophy [71, 72]. In a model
of muscular dystrophy not associated with DGC defects
but instead caused by defective collagen IV, a component
of the extracellular matrix, mitochondrial dysfunction was
shown to be a major source of ROS. Additionally, when
ROS production was suppressed, oxidation of myoﬁbrillar
proteins was reduced and improved contractile perfor-
mance [73]. Therefore, cellular mechanisms downstream
of mitochondrial defects may be an important step in
the process by which DGC mutations eventually result in
myoﬁber damage and cause muscle disease.
Normal excitation-contraction coupling has been sug-
gested to be aﬀected by an increase in cellular calcium
concentration and may also be an important contributor to
muscle weakness in these diseases [74, 75]. Elevated calcium
can also directly impair muscle function by increasing the
activity of calcium-dependent proteases like calpains which
can cleave myoﬁbrillar proteins [76–78]. While the genetic
and pharmacological inhibition of calpains may alleviate
several pathological features in mdx muscle [79–81], such
experiments have yielded inconsistent results and may be in
partduetocompensatoryincreasesincalpainactivityand/or
al a c ko fe ﬃcacy of the proposed inhibitors [82].
Several of these studies have demonstrated that intra-
cellular calcium is elevated in dystrophic muscle, and that
this can lead to a number of deleterious eﬀects to the cell
and contribute to a decline in contractile function. More
importantly, these studies have provided several alternatives
by which calcium permeability and/or intracellular calcium
may be increasing that are independent from direct entry of
calciumthroughsarcolemmatears.However,itisstillunclear
just how distinct genetic mutations that aﬀect the function
of the DGC can alter activity of the various calcium channels
that have been proposed. While inhibition of calcium entry
has been shown to be beneﬁcial in the animal models
addressed, it is important to note that muscle disease was
still present in these animals, albeit it to a lesser degree.
This suggests that altered calcium homeostasis, whether it is
through membrane tears or from altered activity of calcium
channels, may not be the only mechanism downstream of
genetic mutations that results in muscle damage.
6.Laminin-DependentIntracellularSignaling
through the DGC
Laminins exist as heterotrimeric proteins composed of
speciﬁc combinations of α, β,a n dγ subunits and are
diﬀerentially expressed in multiple cell types. Laminin-211
(α2/β1/γ1) is expressed in the extracellular matrix of adult
skeletal muscle and is bound with high aﬃnity by α-DG6 Journal of Biomedicine and Biotechnology
and α7β1 integrin. Mutations that aﬀect α2 laminin, as is
the case in the dy/dy mouse and in congenital muscular
dystrophy 1A, result in muscular dystrophy as a result of
lost interactions with either or both laminin receptors [24–
26]. Although laminin is the major ligand of dystroglycan
by which a connection is forged between the DGC and
the extracellular matrix in skeletal muscle, laminin-211
deﬁcient muscle is not susceptible to contraction-induced
damage and does not typically show increased uptake of
cell impermeant dye (reviewed in Section 4). Despite the
lack of evidence for increased muscle damage, many ﬁbers
of laminin-deﬁcient muscle are apoptotic [83], which is
thought to signiﬁcantly contribute to muscle disease. Both
pharmacological and genetic inhibition of apoptosis (e.g.,
Bcl-2 overexpression, Bax inactivation) have been shown to
ameliorate dystrophy in laminin-α2-deﬁcient animal models
[84–87]. Because there appears to be a lack of sarcolemmal
damage, the mechanism by which apoptosis occurs in this
disease may be independent of elevations in intracellular
calcium. Alternatively, increases in apoptosis may be due
to disruptions in downstream cell survival signaling as a
result of lost interactions between laminin and its two major
receptors in skeletal muscle.
Potential increases in survival signaling though laminin
receptors in muscle could be the basis for results of a recent
study that demonstrated an improvement of dystrophy
in mdx mice upon injection of soluble laminin-111, a
laminin isoform not normally expressed in skeletal muscle
[88]. While the mechanism of this eﬀect is unclear, the
beneﬁt of laminin-111 injections may be due to either
upregulation of α7-integrin-mediated signaling or integrin-
mediated stabilization of the sarcolemma [88]. However, a
transgenicapproachtodeliverlaminin-111toskeletalmuscle
failed to beneﬁt mdx mice [89] despite its rescue of muscular
dystrophy in laminin-α2-deﬁcient muscle [90, 91]. So while
lamininα1andα2arenormallyexpressedindiﬀerenttissues,
they appear to be functionally similar in promoting muscle
cell survival. Whether this important function of laminin in
muscle can be targeted therapeutically in all forms of DGC-
deﬁcient muscular dystrophy is still debatable.
Integrins are formed as heterodimers of α and β subunits
and the predominant alpha isoform expressed in diﬀerenti-
ated skeletal muscle, α7 integrin, forms dimers with β1t o
form a laminin receptor. Mutations in α7 integrin result in
muscular dystrophy in patients and in animal models, and
al o s so fα7 integrin in muscle has been shown to predomi-
nantly aﬀect the structure and function of the myotendinous
junction, where α7β1 integrin is highly expressed [92–94].
α7β1 integrin is also expressed at costameres and, similar to
α-dystroglycan, can associate intracellularly with cytoskeletal
proteins and may contribute to mechanical stability of the
sarcolemma [48]. Animals lacking both dystrophin and α7
integrin display a much more severe form of muscular
dystrophy than animals lacking either protein alone, which
suggests that both laminin receptors may be required at the
sarcolemma and can potentially compensate for one another
[95]. Transgenic overexpression of α7 integrin can par-
tially alleviate muscle disease in dystrophin/utrophin double
knock-outmiceindependentlyofanychangeinexpressionof
DGCcomponents[49,96].However,integrinsareassociated
with a number of signaling pathways and can alter AKT
and MAP kinase activity in a contraction-dependent manner
[97]. Therefore, some of the improvement observed when
integrins are overexpressed in dystrophic muscle may be
in part due to changes in cell signaling rather than direct
prevention of sarcolemma damage.
While the integrins may function as laminin-dependent
signaling receptors in skeletal muscle [98], whether dystro-
glycanandtheDGCmaysimilarlyparticipateindownstream
signal transduction cascades is less clear. Rather than simply
serving as a membrane “stabilizer”, dystrophin has also been
proposed to serve as a sensor for membrane tension and
function early in the development of skeletal muscle [99].
The authors of this early study proposed that this function of
the DGC may be achieved through either interactions with
stretch-activated cation channels or through regulation of
a downstream signaling mechanism analogous to integrin
signaling.Suchsignalingwouldlikelybeimportantforeither
growth of diﬀerentiated ﬁbers or for mediating prolifer-
ation or fusion of satellite cells with regenerating ﬁbers.
Interestingly, when the dystroglycan gene was speciﬁcally
targeted in diﬀerentiated skeletal muscle using cre-loxP-
mediated recombination, the phenotype was surprisingly
mild compared to other models of DGC-related muscular
dystrophy [100]. The residual expression of dystroglycan
in satellite cells suggested that dystroglycan might have
an unappreciated role in this cell type, which could be
important for either cell signaling within satellite cells or
for interactions with the basal lamina [100]. However, how
the DGC may be functioning in muscle regeneration is not
known.
Given the critical role of laminin in promoting cell
survival signaling in muscle and the existence of two
possible receptors that might mediate its eﬀects, dissecting
the molecular mechanisms of each would certainly be a
key advance towards understanding how disruptions can
result in muscle disease. A truncated form of laminin-α1
was recently generated that lacks LG domains 4-5 and can
preventdystroglycanbindingwhileretainingtheLGdomains
necessary for laminin interactions with integrins. In contrast
to full length laminin-α1, when this truncated laminin-α1
was transgenically expressed in laminin-α2-deﬁcient muscle,
several ﬁbers in select muscle groups were still apoptotic
[101]. Because transgenic expression of full length laminin-
α1 can fully rescue the dy/dy phenotype, this suggests that
interactions between dystroglycan and laminin are also likely
important for cell survival signaling. This is the ﬁrst study
to our knowledge that directly implicates dystroglycan in
laminin dependent survival signaling in muscle in vivo and
suggeststhatdisruption ofdystroglycan-dependentsignaling
may also contribute to the pathology of muscular dystrophy.
Several studies using primarily cell culture systems have
shown that the DGC may be capable of participating as a
scaﬀold for various signal transduction cascades (Figure 2).
β-Dystroglycan is capable of binding multiple signaling
and adaptor proteins known to be important for myoblast
diﬀerentiation and cell survival signaling [102–105]. The c-
terminus of β-dystroglycan contains a proline-rich regionJournal of Biomedicine and Biotechnology 7
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Figure 2: The dystrophin-glycoprotein complex may participate in laminin-dependent signaling in skeletal muscle. Interactions shown in
blue indicate interactions that have been shown to be increased when laminin is bound to dystroglycan. Interactions in pink indicate those
that have been shown to be increased following a muscle contraction protocol. Since the phosphorylation of β-dystroglycan can bind a
number of other SH2-domain containing proteins and can also interact with Grb2, it may participate in additional signal transduction
cascades that have not yet been identiﬁed. It is important to remember that in many cases, these interactions have been studied in cell culture
systems and the relevance of these interactions in muscle in vivo has not been extensively studied.
that can bind Grb2, a well known adaptor protein [102,
106] and may be important for recruiting additional com-
ponents of the MAP kinase pathway [104]. Dystroglycan
can also be phosphorylated at tyrosine892 near the c-
terminus of β-DG [103, 107] and may function to regulate
interactions between dystrophin and caveolin-3 [107, 108].
This phosphorylation has also been shown to be adhesion
dependent and enables dystroglycan to recruit several SH2-
domain containing proteins, including c-Src and Fyn, to
the sarcolemma [109]. In an unrelated study, these two
kinases were also shown to be associated with the DGC and
functioned to phosphorylate the DGC protein syntrophin
[105]. In the presence of laminin, syntrophin was shown
to associate with the DGC and mediate downstream Rac1
signaling that led to increased activity of c-jun. This result
was suggested to explain how increased doses of laminin in
vitro led to a dose-dependent increase in cell proliferation in
C2C12 myoblasts [110]. An increase in Rac1 signaling was
also observed following muscle contraction, which suggested
that interactions between laminin and dystroglycan are
important for enabling the DGC to function as a laminin-
dependent mechanoreceptor [105].
The PI3K/AKT pathway is an important signaling path-
way essential for muscle cell survival, growth, and hyper-
trophy that has been suspected to function downstream
of the DGC. Disruption of laminin/dystroglycan binding
in vitro by antibody blockade results in a decrease in
PI3K-mediated phosphorylation of AKT and is associated
with an increase in apoptosis [111]. This result may be
mediated in part through interactions of the DGC with
heterotrimeric G-proteins, which has also been shown to be
laminin-dependent. In the presence of laminin, dystroglycan
can be immunoprecipitated in a complex with Gβγ and
PI3K and leads to an increase in AKT activation [112].
Therefore, the authors of this study concluded that, in
muscular dystrophies where the DGC is disrupted, loss of
an interaction with Gβγ can impair PI3K signaling and
may contribute to disease pathology. Several studies have
demonstratedperturbationsinAKTsignalinginmdx muscle
but generally have demonstrated an increase in AKT activity
rather than a decrease that would be predicted by these cell
culture studies [112, 113]. This potentially could be due
to increased AKT signaling downstream of α7β1 integrin,
which is upregulated in mdx muscle [114] and has been
shown to be beneﬁcial when overexpressed in dystrophic
muscle either directly [115] or downstream of IGF-1 [116–
118].
While the potential loss of PI3K/AKT signaling down-
stream of laminin binding may impact muscle function
through its eﬀect on cell survival or growth, skeletal muscle
function may also be compromised due to increases in
activity of the ubiquitin-proteasome system (UPS) [119].
MuRF1 and MAFbx/atrogin-1 are important mediators of
skeletal muscle atrophy that function to ubiquitinate target
proteins which subsequently results in their destruction
by the proteasome [119]. In a recent study, decreased
phosphorylation of AKT was demonstrated in laminin-
deﬁcient muscle and was associated with an increase in total
amount of ubiquitinated protein [120]. Additionally, phar-
macological inhibition of the ubiquitin-proteasome pathway
in laminin-deﬁcient animals resulted in an amelioration
of several pathological features of the disease. This led
the authors to conclude that impaired laminin-dependent
signaling in dystrophic muscle may also be impacting
the UPS and contributing to muscle disease. Although a
number of signaling pathways are known to be impor-
tant for skeletal muscle growth, the exact contributions
of disrupted dystroglycan-dependent or integrin-dependent
signaling in dystrophic muscle still needs to be formally
addressed.8 Journal of Biomedicine and Biotechnology
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7. DirectRole of the Dystrophin-Glycoprotein
Complex in Force Transmission
While muscle damage is hypothesized to be important
in the pathogenesis and progression of DGC-associated
muscular dystrophy, dystrophic muscle displays considerable
muscle weakness even in very early stages of the disease.
This weakness, expressed as a reduction in speciﬁc force
normalized to the cross sectional area of the muscle, occurs
prior to muscular atrophy and can even be measured in the
presence of pseudohypertrophy in early phases of the disease
[121, 122]. Our studies and the studies of others, in soleus
muscle of DGC-deﬁcient muscular dystrophies, demonstrate
that the soleus muscle is also weak and this weakness is
completely independent of an increased susceptibility of
the muscle to damage [38, 45]. Therefore, muscle damage
that results as a consequence of contraction-induced injury
cannot fully explain the muscle weakness in DGC-associated
muscular dystrophy.
Given the location of the DGC at costameres in muscle,
several investigators have hypothesized that the DGC might
contribute to “lateral transmission of force” from the sar-
comere to the lateral extracellular matrix [123–126]. While
the concept of longitudinal force generated in sarcomeres
and transmitted down myoﬁbrils in muscle to the tendon
is well studied, the concept of lateral force transmission is
less well appreciated. This concept of lateral transmission
of force in muscle was ﬁrst described in frog muscle by
Street in the early 1980’s [127]. In these studies, force was
shown to be transmitted laterally from a single dissected
ﬁber to the ﬁbers ﬂanking it in a muscle ﬁber bundle, with
little or no decrement. Formal proof that the DGC was
important in lateral transmission of force in muscle was
lacking. Recently, we developed a novel yoke apparatus to
directly measure the transmission of force from the muscle
laterallyto the extracellularmatrix and the epimysium [128].
Applying this approach to mdx muscle, we showed for the
ﬁrst time that loss of DGC function in tibialis anterior
musclesofmdxmicewassuﬃcienttocauseanapproximately
40% loss in lateral force transmission in the muscles. While
the precise contribution of each of the other components of
the cytoskeleton, the costamere, and the extracellular matrix
to the lateral transmission of force in muscle remains to
be elucidated, the loss of lateral transmission of force may
help explain how loss of the DGC at the lateral membrane
contributes muscle weakness and fragility. Furthermore, the
lateral transmission of force might be critical in transmitting
force around the sites of focal myoﬁber injury in whole
muscle and may help explain the markedly enhanced force
deﬁcits caused by lengthening contractions observed in fast
muscles of DGC deﬁcient animals (Figure 3).
8. Conclusions
Several studies have suggested that mutations aﬀecting the
DGC result in muscular dystrophy due to the importance
of this complex in preserving sarcolemmal integrity. This
role of the sarcolemma in muscular dystrophy is further
supported by the observation that mutations that aﬀect
membrane repair can also result in muscle disease [40].
While several reports have demonstrated deﬁcits in force
production in dystrophic muscle in response to contraction-
induced damage, it is not clear whether these defects
are directly due to changes in sarcolemma integrity [37].
Additionally, mutations that aﬀect the DGC have been
shown to result in a muscle disease that variably aﬀects
the diaphragm, EDL, and soleus muscles. Therefore, an
increased susceptibility to mechanical injury does not appear
to be an essential step in the dystrophic process that leads
to muscle weakness and the progressive decline in muscle
function, and incidentally, cannot always account for other
observedcellulardisruptionssuchasdiﬀerencesinapoptosis.
Animportantdownstreameventthathasbeenattributed
to increased sarcolemma permeability through membrane
tears is an increase in intracellular calcium. This rise in
calcium is capable of negatively impacting skeletal muscle
in a multitude of ways and may in fact be an impor-
tant contributor to the pathology in these diseases. TheJournal of Biomedicine and Biotechnology 9
mechanism by which DGC mutations can alter the activity
of calcium channels is not clear but would support a
hypothesis that membrane damage is not an essential event
that precedes changes in calcium permeability. Although
changes in calcium permeability alone can result in muscle
disease, it is unlikely that this is the sole mechanism by
which DGC mutations result in muscular dystrophy since
interventions that have restored calcium homeostasis have
not completely eliminated the disease.
Another consequence of gene mutations that have been
shown to be relevant to disease pathology in muscular
dystrophy are disruptions in signaling pathways that may be
essential to enable skeletal muscle to adapt and respond to
ongoing cycles of contraction and relaxation. Laminin muta-
tions result in muscle disease concomitant with increases in
apoptosis and a recent study suggests that this defect may
be mediated in part through the DGC. In light of emerging
evidence that membrane damage is not essential, this gives
credence to several in vitro studies that have suggested that
dystroglycan and the DGC may be participating in cell
survival signaling. Therefore, dystroglycan in combination
with other components in the DGC may be serving a
function similar to that of α7β1 integrin, which has been
moreextensivelydemonstratedinmechano-relatedsignaling
[48, 49].
Many recent studies have demonstrated pharmacological
and genetic interventions that have resulted in a dramatic
improvement of the dystrophic pathology without any obvi-
ous protection of the sarcolemma from mechanical dam-
age [129–131]. Discovery of additional signaling pathways
directly downstream of the DGC, either those important for
survival signaling or related to altered calcium homeostasis,
may also serve as potential targets for pharmacological
interventions to reduce disease pathology.
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